Artiva Biotherapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 24, 2025
ARTV$4.22+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(in thousands)
| YEAR ENDED DECEMBER 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities: | ||
| Net loss | $(65,373) | $(28,720) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 2,431 | 2,266 |
| Stock-based compensation | 6,980 | 7,053 |
| Change in fair value of SAFEs (including related party amounts of $2,911 and $573, respectively) | 3,597 | 707 |
| Accretion of discounts and amortization of premiums on investments, net | (2,342) | (456) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable (including related party amounts of $569 and $(569), respectively) | 1,034 | (510) |
| Other receivables (including related party amounts of $607 and $(607), respectively) | 578 | (724) |
| Prepaid expenses and other current assets | (1,965) | 516 |
| Other long-term assets | 125 | 139 |
| Accounts payable (including related party amounts of $76 and $51, respectively) | 519 | (408) |
| Accrued expenses (including related party amounts of $(1,447) and $(971), respectively) | (659) | (912) |
| Operating lease right-of-use asset and lease liabilities, net | 43 | 145 |
| Deferred revenue | — | (26,526) |
| Net cash used in operating activities | (55,032) | (47,430) |
| Investing activities: | ||
| Purchases of property and equipment | (642) | (3,258) |
| Purchases of short-term investments | (176,171) | (49,517) |
| Maturities of short-term investments | 56,350 | 26,800 |
| Net cash used in investing activities | (120,463) | (25,975) |
| Financing activities: | ||
| Proceeds from issuance of common stock, net of commissions | 166,507 | — |
| Proceeds from issuance of simple agreements for future equity (including related party amounts of $0 and $19,742, respectively) | — | 24,393 |
| Proceeds from exercise of stock options | 51 | 10 |
| Payments on finance leases | (149) | — |
| Cash paid in connection with IPO offering costs | (4,183) | — |
| Repurchase of restricted stock | — | (12) |
| Net cash provided by financing activities | 162,226 | 24,391 |
| Net decrease in cash, cash equivalents and restricted cash | (13,269) | (49,014) |
| Cash, cash equivalents and restricted cash at beginning of period | 53,762 | 102,776 |
| Cash, cash equivalents and restricted cash at end of period | $40,493 | $53,762 |
| Reconciliation of cash, cash equivalents and restricted cash to the balance sheet: | ||
| Cash and cash equivalents | $40,235 | $53,504 |
| Restricted cash | 258 | 258 |
| Total cash, cash equivalents and restricted cash | $40,493 | $53,762 |
| Supplemental disclosures of cash flow information: | ||
| Cash paid during the period for: | ||
| Income taxes | $— | $83 |
| Supplemental disclosures of noncash activities: | ||
| Property and equipment purchases in accounts payable and accrued liabilities | $57 | $18 |
| Conversion of SAFE notes to common stock | $28,697 | $— |
| Conversion of preferred stock to common stock | $216,413 | $— |
| Non-cash additions to financing leases | $241 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.